Karus Therapeutics
  • Home
  • About Karus
    • At a glance
    • Leadership
    • Investors
  • Research & Development
  • Partnering
  • Media Centre
    • Press Releases
    • Events
    • In the News
    • Publications
    • Abstracts
  • Contact Us
  • Menu Menu

Media Centre

Publications

Publications

Design and Development of Novel, Highly-Selective HDAC6 Inhibitors for the Treatment of Cancer

3 November 2014/in Abstracts, Publications /by circlek

Design and Development of Novel, Highly-Selective HDAC6 Inhibitors for the Treatment of Cancer.
Cecil A., Rogers H., Bone E., Colman L., Finan P., Haque K., Lensun L., Roitt R., Silva F., Ward P., Whale A., Shuttleworth S.
NCRI Meeting, Liverpool, UK, November 3, 2014, A114.

/wp-content/uploads/2019/04/logo_karustx.png 0 0 circlek /wp-content/uploads/2019/04/logo_karustx.png circlek2014-11-03 12:11:462019-07-11 16:08:04Design and Development of Novel, Highly-Selective HDAC6 Inhibitors for the Treatment of Cancer

Design and Development of a Novel Series of Orally-Active, Selective PI3K-p110ß/δ Inhibitors for the Treatment of Cancer (NCRI Meeting)

3 November 2014/in Abstracts, Publications /by circlek

Design and Development of a Novel Series of Orally-Active, Selective PI3K-p110ß/d Inhibitors for the Treatment of Cancer.
Cecil A., Rogers H., Bone E., Colman L., Finan P., Haque K., Lensun L., Roitt S., Silva F., Ward P., Whale A. Shuttleworth S.
NCRI Meeting, Liverpool, UK, November 3, 2014, A143.

/wp-content/uploads/2019/04/logo_karustx.png 0 0 circlek /wp-content/uploads/2019/04/logo_karustx.png circlek2014-11-03 12:00:132019-07-11 16:08:08Design and Development of a Novel Series of Orally-Active, Selective PI3K-p110ß/δ Inhibitors for the Treatment of Cancer (NCRI Meeting)

Design and Development of a Novel Series of Orally-Active, Selective PI3K-p110ß/δ Inhibitors for the Treatment of Cancer (San Diego)

5 April 2014/in Abstracts, Publications /by circlek

Design and Development of a Novel Series of Orally-Active, Selective PI3K-p110ß/δ Inhibitors for the Treatment of Cancer.
Shuttleworth S.J., Bone E.A., Cecil A.R.L., Colman L., Fulton R., Haque K., Hill T.J., McGovern Y., Nodes W.J., Rogers H., Silva F.A., Whale A.D.
Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr LB-7.

/wp-content/uploads/2019/04/logo_karustx.png 0 0 circlek /wp-content/uploads/2019/04/logo_karustx.png circlek2014-04-05 12:12:472019-07-11 16:08:13Design and Development of a Novel Series of Orally-Active, Selective PI3K-p110ß/δ Inhibitors for the Treatment of Cancer (San Diego)

Design and Development of a Novel Series of HDAC6-Selective Inhibitors for the Treatment of Cancer

5 April 2014/in Abstracts, Publications /by circlek

Design and Development of a Novel Series of HDAC6-Selective Inhibitors for the Treatment of Cancer.
Shuttleworth S.J., Bone E.A; Cecil A.R.L., Colman L., Fulton R., Hill T.J., McCormick S., Nodes W.J., Rogers H., Silva F.A., Tomassi C.D., Whale A.D.
Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr LB-8.

/wp-content/uploads/2019/04/logo_karustx.png 0 0 circlek /wp-content/uploads/2019/04/logo_karustx.png circlek2014-04-05 12:00:132019-07-11 16:08:19Design and Development of a Novel Series of HDAC6-Selective Inhibitors for the Treatment of Cancer

Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors.

1 January 2011/in Publications /by circlek

Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors.
Shuttleworth SJ, Silva FA, Cecil AR, Tomassi CD, Hill TJ, Raynaud FI, Clarke PA, Workman P.
Curr Med Chem. 2011, 18(18), p2686-714.

/wp-content/uploads/2019/04/logo_karustx.png 0 0 circlek /wp-content/uploads/2019/04/logo_karustx.png circlek2011-01-01 12:16:512019-04-16 12:17:24Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors.
Page 4 of 512345

Categories

  • Press Releases
  • Events
  • In the News
  • Publications
  • Abstracts
View archive
  • Privacy Policy

© Karus Therapeutics. All rights reserved

Registered in England & Wales No 05490954
VAT No 871 4126 33

LinkedIn

Created by Instinctif Partners

Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

OKLearn more

Cookie and Privacy Settings



How we use cookies

We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.

Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to deliver the website, refuseing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.

We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.

We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.

Google Analytics Cookies

These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.

If you do not want that we track your visit to our site you can disable tracking in your browser here:

Other external services

We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

Google Webfont Settings:

Google Map Settings:

Google reCaptcha Settings:

Vimeo and Youtube video embeds:

Other cookies

The following cookies are also needed - You can choose if you want to allow them:

Privacy Policy

You can read about our cookies and privacy settings in detail on our Privacy Policy Page.

Privacy Policy
Accept settingsHide notification only